TNF Pharmaceuticals

TNF Pharmaceuticals is a clinical-stage biotech focused on modulating immunometabolic pathways to treat autoimmune, inflammatory, and age-related diseases. Its core achievement is advancing MYMD-1®, an oral TNF-alpha inhibitor with Phase 2 success in sarcopenia, into planned Phase 3 trials, with a parallel program in synthetic cannabinoids. In a significant strategic pivot, the company has licensed exclusive global rights to a light-speed computing accelerator for cryptocurrency, signaling a major diversification beyond its traditional biopharma focus. This move aims to create a dual-track business model combining clinical development with high-tech commercialization.

A small molecule platform focused on oral modulation of immunometabolic pathways, including next-generation TNF-alpha inhibition with blood-brain barrier penetration and high-potency synthetic cannabinoid receptor agonism.

In sarcopenia, competition is nascent, offering a first-mover opportunity. In autoimmune diseases, MYMD-1® faces entrenched biologic TNF inhibitors and oral JAK inhibitors. Supera-CBD competes with approved plant-derived CBD and other synthetic cannabinoids. The computing venture competes with established semiconductor and crypto-mining hardware giants.